HYDREIGHT TECHNOLOGIES INC (NURS.CA) Fundamental Analysis & Valuation

TSX-V:NURS • CA44877L1013

Current stock price

4.23 CAD
+0.17 (+4.19%)
Last:

This NURS.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

5

1. NURS.CA Profitability Analysis

1.1 Basic Checks

  • NURS had positive earnings in the past year.
  • In the past year NURS had a positive cash flow from operations.
NURS.CA Yearly Net Income VS EBIT VS OCF VS FCFNURS.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 -2M -4M

1.2 Ratios

  • With an excellent Return On Assets value of 2.04%, NURS belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
  • NURS's Return On Equity of 4.79% is amongst the best of the industry. NURS outperforms 100.00% of its industry peers.
  • NURS has a Return On Invested Capital of 1.46%. This is amongst the best in the industry. NURS outperforms 90.00% of its industry peers.
Industry RankSector Rank
ROA 2.04%
ROE 4.79%
ROIC 1.46%
ROA(3y)-98.35%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NURS.CA Yearly ROA, ROE, ROICNURS.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 500 1K 1.5K

1.3 Margins

  • The Profit Margin of NURS (1.85%) is better than 90.00% of its industry peers.
  • With an excellent Operating Margin value of 1.48%, NURS belongs to the best of the industry, outperforming 90.00% of the companies in the same industry.
  • NURS has a Gross Margin (29.16%) which is in line with its industry peers.
  • In the last couple of years the Gross Margin of NURS has declined.
Industry RankSector Rank
OM 1.48%
PM (TTM) 1.85%
GM 29.16%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.69%
GM growth 5YN/A
NURS.CA Yearly Profit, Operating, Gross MarginsNURS.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 0 50 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. NURS.CA Health Analysis

2.1 Basic Checks

  • NURS has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • The number of shares outstanding for NURS has been increased compared to 1 year ago.
  • There is no outstanding debt for NURS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NURS.CA Yearly Shares OutstandingNURS.CA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 10M 20M 30M 40M
NURS.CA Yearly Total Debt VS Total AssetsNURS.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 1M 2M 3M

2.2 Solvency

  • An Altman-Z score of 12.00 indicates that NURS is not in any danger for bankruptcy at the moment.
  • NURS has a better Altman-Z score (12.00) than 80.00% of its industry peers.
  • NURS has a Debt/Equity ratio of 0.83. This is a neutral value indicating NURS is somewhat dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.83, NURS is doing worse than 60.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.83
Debt/FCF N/A
Altman-Z 12
ROIC/WACC0.18
WACC8.14%
NURS.CA Yearly LT Debt VS Equity VS FCFNURS.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 -500K -1M -1.5M

2.3 Liquidity

  • NURS has a Current Ratio of 4.47. This indicates that NURS is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of NURS (4.47) is better than 90.00% of its industry peers.
  • NURS has a Quick Ratio of 4.47. This indicates that NURS is financially healthy and has no problem in meeting its short term obligations.
  • NURS has a better Quick ratio (4.47) than 90.00% of its industry peers.
Industry RankSector Rank
Current Ratio 4.47
Quick Ratio 4.47
NURS.CA Yearly Current Assets VS Current LiabilitesNURS.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 1M 2M 3M 4M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. NURS.CA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 128.24% over the past year.
  • Looking at the last year, NURS shows a very strong growth in Revenue. The Revenue has grown by 59.17%.
  • NURS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 137.35% yearly.
EPS 1Y (TTM)128.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%426.09%
Revenue 1Y (TTM)59.17%
Revenue growth 3Y137.35%
Revenue growth 5YN/A
Sales Q2Q%132.42%

3.2 Future

  • Based on estimates for the next years, NURS will show a very strong growth in Earnings Per Share. The EPS will grow by 267.38% on average per year.
  • Based on estimates for the next years, NURS will show a very strong growth in Revenue. The Revenue will grow by 130.31% on average per year.
EPS Next Y391.35%
EPS Next 2Y457.98%
EPS Next 3Y267.39%
EPS Next 5YN/A
Revenue Next Year125.3%
Revenue Next 2Y207.15%
Revenue Next 3Y130.32%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
NURS.CA Yearly Revenue VS EstimatesNURS.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M
NURS.CA Yearly EPS VS EstimatesNURS.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 0.1 0.2 0.3 0.4

More info and screens

Find the best growth stocksShow best growing peers

4

4. NURS.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 423.00, which means the current valuation is very expensive for NURS.
  • Based on the Price/Earnings ratio, NURS is valued cheaply inside the industry as 90.00% of the companies are valued more expensively.
  • NURS's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.47.
  • A Price/Forward Earnings ratio of 13.96 indicates a correct valuation of NURS.
  • NURS's Price/Forward Earnings ratio is rather cheap when compared to the industry. NURS is cheaper than 100.00% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of NURS to the average of the S&P500 Index (22.62), we can say NURS is valued slightly cheaper.
Industry RankSector Rank
PE 423
Fwd PE 13.96
NURS.CA Price Earnings VS Forward Price EarningsNURS.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 100 200 300 400

4.2 Price Multiples

  • NURS's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. NURS is cheaper than 80.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 338.14
NURS.CA Per share dataNURS.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 0.2 0.3 0.4

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • A more expensive valuation may be justified as NURS's earnings are expected to grow with 267.38% in the coming years.
PEG (NY)1.08
PEG (5Y)N/A
EPS Next 2Y457.98%
EPS Next 3Y267.39%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NURS.CA Dividend Analysis

5.1 Amount

  • NURS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NURS.CA Fundamentals: All Metrics, Ratios and Statistics

HYDREIGHT TECHNOLOGIES INC

TSX-V:NURS (4/23/2026, 7:00:00 PM)

4.23

+0.17 (+4.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)11-26
Earnings (Next)05-05
Inst Owners1.37%
Inst Owner ChangeN/A
Ins Owners1.89%
Ins Owner ChangeN/A
Market Cap225.88M
Revenue(TTM)24.48M
Net Income(TTM)453.30K
Analysts80
Price Target9.95 (135.22%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-12.44%
Min Revenue beat(2)-33.59%
Max Revenue beat(2)8.7%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)14.71%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-14.29%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.33%
Valuation
Industry RankSector Rank
PE 423
Fwd PE 13.96
P/S 9.23
P/FCF N/A
P/OCF 310.45
P/B 23.84
P/tB 31.51
EV/EBITDA 338.14
EPS(TTM)0.01
EY0.24%
EPS(NY)0.3
Fwd EY7.16%
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)0.01
OCFY0.32%
SpS0.46
BVpS0.18
TBVpS0.13
PEG (NY)1.08
PEG (5Y)N/A
Graham Number0.199787 (-95.28%)
Profitability
Industry RankSector Rank
ROA 2.04%
ROE 4.79%
ROCE 2.03%
ROIC 1.46%
ROICexc N/A
ROICexgc N/A
OM 1.48%
PM (TTM) 1.85%
GM 29.16%
FCFM N/A
ROA(3y)-98.35%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.69%
GM growth 5YN/A
F-Score5
Asset Turnover1.1
Health
Industry RankSector Rank
Debt/Equity 0.83
Debt/FCF N/A
Debt/EBITDA 12.5
Cap/Depr 535.2%
Cap/Sales 5.89%
Interest Coverage 250
Cash Conversion 115.22%
Profit Quality N/A
Current Ratio 4.47
Quick Ratio 4.47
Altman-Z 12
F-Score5
WACC8.14%
ROIC/WACC0.18
Cap/Depr(3y)341%
Cap/Depr(5y)N/A
Cap/Sales(3y)3.62%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)128.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%426.09%
EPS Next Y391.35%
EPS Next 2Y457.98%
EPS Next 3Y267.39%
EPS Next 5YN/A
Revenue 1Y (TTM)59.17%
Revenue growth 3Y137.35%
Revenue growth 5YN/A
Sales Q2Q%132.42%
Revenue Next Year125.3%
Revenue Next 2Y207.15%
Revenue Next 3Y130.32%
Revenue Next 5YN/A
EBIT growth 1Y124.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year570.31%
EBIT Next 3Y334.94%
EBIT Next 5YN/A
FCF growth 1Y46.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y313.05%
OCF growth 3YN/A
OCF growth 5YN/A

HYDREIGHT TECHNOLOGIES INC / NURS.CA Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for HYDREIGHT TECHNOLOGIES INC?

ChartMill assigns a fundamental rating of 5 / 10 to NURS.CA.


What is the valuation status of HYDREIGHT TECHNOLOGIES INC (NURS.CA) stock?

ChartMill assigns a valuation rating of 4 / 10 to HYDREIGHT TECHNOLOGIES INC (NURS.CA). This can be considered as Fairly Valued.


What is the profitability of NURS stock?

HYDREIGHT TECHNOLOGIES INC (NURS.CA) has a profitability rating of 5 / 10.


Can you provide the financial health for NURS stock?

The financial health rating of HYDREIGHT TECHNOLOGIES INC (NURS.CA) is 5 / 10.


What is the earnings growth outlook for HYDREIGHT TECHNOLOGIES INC?

The Earnings per Share (EPS) of HYDREIGHT TECHNOLOGIES INC (NURS.CA) is expected to grow by 391.35% in the next year.